Tagged with strategy

Egypt Emad Graiss, managing director of Merck North East Africa, explains what it takes to successfully steer a company through a period of economic difficulties, while still growing at a fast pace. He also highlights how the Egyptian government has prioritized healthcare and how private companies like Merck are collaborating with…

Korea YongBum Choi, general manager of Ferring Korea, explains how he plans to foster the Ferring values in the local affiliate. Mr Choi also breaks down the stigmas associated with assisted reproductive technologies and lays down Ferring’s ambitious growth strategy through breakthrough products launches every two years in Uro-Oncology & Gastroenterology.…

Egypt Mohamed Swilam, country manager of Roche Egypt, explains how ensuring access to medicine in Egypt is not only related to pricing challenges, but also to support healthcare systems, improve diagnosis, educate and build local skills. He also gives insights into the company’s plans on how to partner with stakeholders across…

Egypt Ahmed Mostafa, country manager of Amgen in Egypt and Iran, explains how the affiliate has been growing by providing end-to-end solutions. He also gives his take on the Egyptian government’s prioritization of healthcare and highlights that there are still improvements needed for bringing biosimilars to Egypt.     How would…

Korea LG Life Sciences is one the early pioneers of innovative drug development in Korea with a diversified portfolio of chemical drugs, vaccines, biosimilars, biologics, and dermo-cosmetics. Its president, Dr Son, explains the reason why he joined the company, his strategy to turn it into a truly global entity, and its…

Egypt Ayman El Deeb, cluster head of Astellas Egypt, highlights how the Egyptian affiliate of Astellas has been performing since its establishment five years ago. He also discusses the need for better patent protection in the country and explains how Astellas is contributing to the country’s reform of the healthcare system.…

China Yuichi Yomasu, president of Daiichi Sankyo China, shares his first impressions of the dynamic but complex Chinese market since he assumed position ten months ago; the strategic importance of the Chinese affiliate to the Group’s overall business, particularly in light of the Group’s transition towards an innovative leader in oncology…

China Tian Wee Ng, managing director (Asia-Pacific) for Pierre Fabre Medicament, shares insight on how the business has evolved in the region, moving from an opportunistic approach to a more strategic one, since his appointment in 2016. He also discusses the value of Pierre Fabre’s oncology portfolio for the region and…

China Rogers Luo Yongqing, global VP and general manager (China), Gilead Sciences, shares the key accomplishments of Gilead in China with six innovative products approved in just 15 months; the strategic significance of Gilead China as the newest affiliate for Gilead globally; and their commitment to maximizing patient access in China…

Korea Min-Young Kim, general manager at Ipsen Korea discusses her strategy to refocus the Korean affiliate away from the toxin market and towards oncology and rare diseases. She also documents Ipsen’s rapid local growth and increasing market share. Miss Kim also gives her assessment of the current drug pricing situation, as…

China Hong Chow, general manager of Roche Pharma China, shares Roche China’s incredible milestones over the past few years, including four pivotal oncology drugs listed on the National Reimbursement Drug List (NRDL) in 2017; the company’s USD 129 million investment in a new innovation center in Shanghai, the third strategic innovation…

France Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service hospital partner in the French healthcare system. Additionally, Søndergaard offers his assessments of the conditions of market access in France…